66 related articles for article (PubMed ID: 2949756)
21. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.
Sodroski J; Goh WC; Rosen C; Campbell K; Haseltine WA
Nature; 1986 Jul 31-Aug 6; 322(6078):470-4. PubMed ID: 3016552
[TBL] [Abstract][Full Text] [Related]
22. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS).
Shearer GM; Bernstein DC; Tung KS; Via CS; Redfield R; Salahuddin SZ; Gallo RC
J Immunol; 1986 Oct; 137(8):2514-21. PubMed ID: 3489767
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of antibodies to AIDS-associated retrovirus in in- and out-patients in Japan.
Ikegami N
AIDS Res; 1986 Dec; 2 Suppl 1():S29-34. PubMed ID: 3103640
[TBL] [Abstract][Full Text] [Related]
24. Advances in the isolation of HTLV-III from patients with AIDS and AIDS-related complex and from donors at risk.
Markham PD; Salahuddin SZ; Popovic M; Patel A; Veren K; Fladager A; Orndorff S; Gallo RC
Cancer Res; 1985 Sep; 45(9 Suppl):4588s-4591s. PubMed ID: 2990690
[TBL] [Abstract][Full Text] [Related]
25. [Activation of the macrophage/lymphocyte system in AIDS, ARC and AIDS risk groups].
Wachter H; Blecha HG; Fuchs D; Hausen A; Hengster P; Hinterhuber H; Reibnegger G; Reissigl H; Rössler H; Schönitzer D
Wien Klin Wochenschr; 1986 Jul; 98(14):449-54. PubMed ID: 3019018
[TBL] [Abstract][Full Text] [Related]
26. AIDS-related benign lymphadenopathy and malignant lymphoma: clinical aspects and virologic interactions.
Abrams DI; Kaplan LD; McGrath MS; Volberding PA
AIDS Res; 1986 Dec; 2 Suppl 1():S131-40. PubMed ID: 3828009
[TBL] [Abstract][Full Text] [Related]
27. Tuberculosis--United States, 1985--and the possible impact of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1986 Feb; 35(5):74-6. PubMed ID: 3080659
[TBL] [Abstract][Full Text] [Related]
28. Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.
Farthing CF; Dalgleish AG; Clark A; McClure M; Chanas A; Gazzard BG
AIDS; 1987 May; 1(1):21-5. PubMed ID: 2962589
[TBL] [Abstract][Full Text] [Related]
29. The acquired immunodeficiency syndrome (AIDS).
Rosen FS
J Clin Invest; 1985 Jan; 75(1):1-3. PubMed ID: 3155526
[TBL] [Abstract][Full Text] [Related]
30. Lymphadenopathic type of Kaposi's sarcoma in a Ugandan child seropositive for LAV/HTLV-III antibodies.
Marquart KH; Müller HA; Hartter P; Oku JC; Ayuko WO
J Trop Med Hyg; 1987 Apr; 90(2):93-4. PubMed ID: 3470530
[TBL] [Abstract][Full Text] [Related]
31. Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS.
Alter HJ; Eichberg JW; Masur H; Saxinger WC; Gallo R; Macher AM; Lane HC; Fauci AS
Science; 1984 Nov; 226(4674):549-52. PubMed ID: 6093251
[TBL] [Abstract][Full Text] [Related]
32. Cyclosporine-induced deterioration in patients with AIDS.
Phillips A; Wainberg MA; Coates R; Klein M; Rachlis A; Read S; Shepherd F; Vellend H; Walmsley S; Halloran P
CMAJ; 1989 Jun; 140(12):1456-60. PubMed ID: 2720530
[TBL] [Abstract][Full Text] [Related]
33. Immunological effects of isoprinosine as a pulse immunotherapy in melanoma and ARC patients.
Pompidou A; Soubrane C; Cour V; Telvi L; Meunier C; Jacquillat C
Cancer Detect Prev Suppl; 1987; 1():457-62. PubMed ID: 2446759
[TBL] [Abstract][Full Text] [Related]
34. Phase I/II trial of thymosin fraction 5 and thymosin alpha one in HTLV-III seropositive subjects.
Schulof RS; Simon GL; Sztein MB; Parenti DM; DiGioia RA; Courtless JW; Orenstein JM; Kessler CM; Kind PD; Schlesselman S
J Biol Response Mod; 1986 Oct; 5(5):429-43. PubMed ID: 3490545
[TBL] [Abstract][Full Text] [Related]
35. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.
Yarchoan R; Klecker RW; Weinhold KJ; Markham PD; Lyerly HK; Durack DT; Gelmann E; Lehrman SN; Blum RM; Barry DW
Lancet; 1986 Mar; 1(8481):575-80. PubMed ID: 2869302
[TBL] [Abstract][Full Text] [Related]
36. The LAV/HTLV-III virus may evade elimination by the immune system by inducing low zone tolerance to itself.
Sharpe RJ; Schweizer RT
Med Hypotheses; 1986 Aug; 20(4):421-7. PubMed ID: 3489879
[TBL] [Abstract][Full Text] [Related]
37. Immunoreconstitution of T-cell impairments in asymptomatic male homosexuals by thymic humoral factor (THF).
Handzel ZT; Berner Y; Segal O; Burstein Y; Buchner V; Pecht M; Levin S; Burstein R; Milchan R; Bentwich Z
Int J Immunopharmacol; 1987; 9(2):165-73. PubMed ID: 3294619
[TBL] [Abstract][Full Text] [Related]
38. Stages in LAV/HTLV-III lymphadenitis. II. Correlation with clinical and immunological findings.
Gerstoft J; Pallesen G; Mathiesen L; Dickmeiss E; Lindhardt BO; Hofmann B; Nielsen CM; Petersen CS; Kroon S
Scand J Immunol; 1987 Jan; 25(1):93-9. PubMed ID: 3810044
[TBL] [Abstract][Full Text] [Related]
39. Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome.
Roberts RB; Laskin OL; Laurence J; Scavuzzo D; Murray HW; Kim YT; Connor JD
Clin Pharmacol Ther; 1987 Oct; 42(4):365-73. PubMed ID: 2444379
[TBL] [Abstract][Full Text] [Related]
40. [Time of onset and regression of D-penicillamine activity, measured by rupture load of rat skin].
Friedrich VL; Zimmermann F
Arzneimittelforschung; 1975 Mar; 25(3):361-3. PubMed ID: 1174031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
